Acadia is adding 22 inpatient psychiatric beds in a unit that had not been in use and can transition yet another 50 beds to inpatient psychiatric beds from various other uses upon the expiration of third-party supplier leases at the end of 2014. Account for this purchase, which was effective January 1, 2014, was $10.5 million in cash. Joey Jacobs, Chairman and Chief Executive Officer of Acadia, commented, We are pleased to complete an effective 2013 and commence 2014 on a solid take note with two acquisitions that provide top quality facilities and exceptional medical staffs to Acadia. The purchase of the Seattle service represented our 7th acquisition for 2013. Including this deal, we added approximately 1,000 beds during 2013, through both acquisitions and the advancement of brand-new beds in existing or de novo services.All rights reserved.
Adamis’ APC-300 inhibits growth of prostate malignancy cells Adamis Pharmaceuticals Company announced today that furthermore to activity in pancreatic cancer and its multiple modes of action, APC-300 significantly inhibits the development of prostate cancer cells. This year 2010, the American Malignancy Society reported that 217,730 men in the U.S. Were diagnosed with prostate cancer and 32,050 were projected to die from the disease. While treatment with surgery and/or radiation is frequently successful, about one-third of sufferers will knowledge disease recurrence.